 |
|
|
| |
N-CORE: sustained virological response rates with peginterferon alfa-2a/ribavirin (PegIFN alfa 2a/RBV) in HCV G2 or 3 patients without rapid virological response
|
| |
| |
Reported by Jules Levin
APASL Liver Week 2013; 6-10 June, Singapore
M.L. Shiffman,1 S. Zeuzem,2 C.P. Berg,3 T. Berg,4 C. de Figueiredo-Mendes,5 G.J. Dore,6 M.L. Ferraz,7 M.C. Mendes-Correa,8 M.Patelli-Lima,9 E.R. Parise,7 A.M. Perez-Rios,10 T. Reuter,11 A.J. Sanyal,12 S.D. Shafran,13 M. Hohmann,14 F. Tatsch,15 H. Cheinquer;16 on behalf of the N-CORE study group
1Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, VA, USA; 2Department of Medicine 1, J.W. Goethe University Hospital, Frankfurt, Germany; 3Department of Internal Medicine 1, University Hospital Tubingen, Tubingen, Germany; 4Hepatolgy Section, Dept of Gastroenterology & Rheumatology, Universitatsklinikum Leipzig, Leipzig, Germany; 5Santa Casa da Misericordia do Rio de Janeiro, Hospital Geral, Rio de Janeiro, Brazil; 6Kirby Institute, The University of New South Wales, Darlinghurst, NSW, Australia; 7Department of Gastroenterology Escola Paulista de Medicina, UNIFESP, Sao Paulo, Brazil; 8Infectious Diseases Research Unit, ABC Foundation Medical School, Sao Paulo, Brazil; 9Medical Sciences, Pontificia Universidade Catolica de Campinas, Sao Paulo, Brazil; 10Centro de Investigacion Farmaceutica Especializada, JAL, Guadalajara, Mexico; 11Centre for Infectious Diseases, Universidade Federal do Espirito Santo, Vitoria, Brazil; 12Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, VA, USA; 13Division of Infectious Diseases, University of Alberta, Edmonton, AB, Canada; 14IST GmbH, Mannheim, Germany; 15F. Hoffmann-La Roche Ltd, Basel, Switzerland; 16Department of Gastroenterology, Hospital das Clinicas de Porto Alegre, Porto Alegre, Brazil
|
| |
|
|
|
|
|
